NCT05292898View on ClinicalTrials.gov

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

January 10, 2025

Study Completion Date

March 31, 2025

Conditions
Acute Lymphocytic Leukemia
Interventions
BIOLOGICAL

LCAR-AIO Cells

LCAR-AIO Cells before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.

Trial Locations (2)

Unknown

Beijing Gobroad BoRen Hospital, Beijing

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER